Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23 - PubMed (original) (raw)
. 2008 Sep;23(9):1509-18.
doi: 10.1359/jbmr.080417.
Affiliations
- PMID: 18442315
- DOI: 10.1359/jbmr.080417
Free article
Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23
Yuji Yamazaki et al. J Bone Miner Res. 2008 Sep.
Free article
Abstract
Fibroblast growth factor (FGF)23 is proposed to play a physiological role in the regulation of phosphate and vitamin D metabolism; deranged circulatory levels of FGF23 cause several diseases with abnormal mineral metabolism. This paper presents a novel approach to analyze the mechanism of action of FGF23 using anti-FGF23 monoclonal antibodies that can neutralize FGF23 activities both in vitro and in vivo. We developed two antibodies (FN1 and FC1) that recognize the N- and C-terminal regions of FGF23, respectively. Both FN1 and FC1 inhibited FGF23 activity in a cell-based Klotho-dependent reporter assay. Their administration caused marked increases in serum phosphate and 1,25D levels in normal mice. These changes were accompanied by altered expression in the kidney of type IIa sodium-phosphate cotransporter, 25-hydroxyvitamin-D-1alpha-hydroxylase, and 24-hydroxylase. Thus, this study using neutralizing antibodies confirms that FGF23 is a physiological regulator of phosphate and vitamin D metabolism. We addressed the mechanism of action for these neutralizing antibodies. Structural analysis of the FGF23/FN1-Fab complex showed that FN1 masked putative FGF receptor-binding sites in the N-terminal domain of FGF23, whereas biochemical analyses showed that FC1 interfered with the association between FGF23 and Klotho by binding to the C-terminal domain of FGF23. Taken together, our results suggest that the N- and C-terminal domains of FGF23 are responsible for association with cognate FGF receptors and Klotho, respectively, and that these interactions are indispensable for FGF23 activity.
Similar articles
- Klotho gene, phosphocalcic metabolism, and survival in dialysis.
Torres PU, Prié D, Beck L, De Brauwere D, Leroy C, Friedlander G. Torres PU, et al. J Ren Nutr. 2009 Jan;19(1):50-6. doi: 10.1053/j.jrn.2008.10.018. J Ren Nutr. 2009. PMID: 19121771 Review. - Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia.
Aono Y, Yamazaki Y, Yasutake J, Kawata T, Hasegawa H, Urakawa I, Fujita T, Wada M, Yamashita T, Fukumoto S, Shimada T. Aono Y, et al. J Bone Miner Res. 2009 Nov;24(11):1879-88. doi: 10.1359/jbmr.090509. J Bone Miner Res. 2009. PMID: 19419316 - Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism.
Shimada T, Yamazaki Y, Takahashi M, Hasegawa H, Urakawa I, Oshima T, Ono K, Kakitani M, Tomizuka K, Fujita T, Fukumoto S, Yamashita T. Shimada T, et al. Am J Physiol Renal Physiol. 2005 Nov;289(5):F1088-95. doi: 10.1152/ajprenal.00474.2004. Epub 2005 Jul 5. Am J Physiol Renal Physiol. 2005. PMID: 15998839 - Klotho converts canonical FGF receptor into a specific receptor for FGF23.
Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T. Urakawa I, et al. Nature. 2006 Dec 7;444(7120):770-4. doi: 10.1038/nature05315. Epub 2006 Oct 29. Nature. 2006. PMID: 17086194 - Reciprocal control of 1,25-dihydroxyvitamin D and FGF23 formation involving the FGF23/Klotho system.
Prié D, Friedlander G. Prié D, et al. Clin J Am Soc Nephrol. 2010 Sep;5(9):1717-22. doi: 10.2215/CJN.02680310. Epub 2010 Aug 26. Clin J Am Soc Nephrol. 2010. PMID: 20798257 Review.
Cited by
- Emerging concepts on the FGF23 regulation and activity.
Rivoira MA, Peralta López ME, Areco V, Díaz de Barboza G, Dionisi MP, Tolosa de Talamoni N. Rivoira MA, et al. Mol Cell Biochem. 2024 Apr 6. doi: 10.1007/s11010-024-04982-6. Online ahead of print. Mol Cell Biochem. 2024. PMID: 38581553 Review. - Dental impact of anti-fibroblast growth factor 23 therapy in X-linked hypophosphatemia.
Lira Dos Santos EJ, Nakajima K, Po J, Hanai A, Zhukouskaya V, Biosse Duplan M, Linglart A, Shimada T, Chaussain C, Bardet C. Lira Dos Santos EJ, et al. Int J Oral Sci. 2023 Dec 6;15(1):53. doi: 10.1038/s41368-023-00259-8. Int J Oral Sci. 2023. PMID: 38052774 Free PMC article. - Variation in the fibroblast growth factor 23 (FGF23) gene associates with serum FGF23 and bone strength in infants.
Enlund-Cerullo M, Holmlund-Suila E, Valkama S, Hauta-Alus H, Rosendahl J, Andersson S, Pekkinen M, Mäkitie O. Enlund-Cerullo M, et al. Front Genet. 2023 May 22;14:1192368. doi: 10.3389/fgene.2023.1192368. eCollection 2023. Front Genet. 2023. PMID: 37284066 Free PMC article. - Osteomalacia in Adults: A Practical Insight for Clinicians.
Arboleya L, Braña I, Pardo E, Loredo M, Queiro R. Arboleya L, et al. J Clin Med. 2023 Apr 5;12(7):2714. doi: 10.3390/jcm12072714. J Clin Med. 2023. PMID: 37048797 Free PMC article. Review. - Self-Administration of Burosumab in Children and Adults with X-Linked Hypophosphataemia in Two Open-Label, Single-Arm Clinical Studies.
Kubota T, Namba N, Tanaka H, Muroya K, Imanishi Y, Takeuchi Y, Kanematsu M, Sun W, Seino Y, Ozono K. Kubota T, et al. Adv Ther. 2023 Apr;40(4):1530-1545. doi: 10.1007/s12325-022-02412-x. Epub 2023 Jan 31. Adv Ther. 2023. PMID: 36719566 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous